Please assess the completion status of the following clinical trial:

Trial Title: A Dose-ranging Study of Fluticasone Furoate (FF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent from at least one parent/ legal guardian to take part in the study.:~* Diagnosis of asthma~* pre-bronchodilator PEF between ≥50% to ≤90% of their best post-bronchodilator value~* Receiving therapy of short acting beta-agonist (SABA) alone, LTM, or ICS (total daily dose \<FP 200mcg or equivalent)Exclusion :~Exclusion Criteria:~* history of life-threatening asthma~* history of asthma exacerbation for asthma within 6 months prior to screening.~* Culture-documented or suspected bacterial or viral infection~* significant abnormality or medical condition~* Present use of any tobacco products

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): Fluticasone Furoate 100mcg inhalation powder once daily in the evening ICS powder
- Arm 2 (Type: ACTIVE_COMPARATOR): Fluticasone Furoate 50mcg inhalation powder once daily in the evening ICS powder
- Arm 3 (Type: ACTIVE_COMPARATOR): Fluticasone Furoate 25mcg inhalation powder once daily in the evening ics powder
- Arm 4 (Type: ACTIVE_COMPARATOR): Fluticasone Propionate 100mcg inhalation powder twice daily ICS powder
- Arm 5 (Type: PLACEBO_COMPARATOR): Placebo inhalation powder once daily in the evening Placebo powder

Based on this trial design, predict the completion outcome and termination type (if applicable).